Potentiating bacterial cancer therapy using hydroxychloroquine liposomes

Area of Science:

• Oncolytic Virotherapy
• Cancer Cell Biology
• Drug Delivery Systems

Background:

• Salmonella VNP20009 shows preclinical anti-tumor efficacy but limited human success.
• Cellular autophagy is a key mechanism limiting Salmonella VNP20009 effectiveness.
• Hydroxychloroquine is an autophagy inhibitor with potential therapeutic applications.

Purpose of the Study:

• To investigate the combined efficacy of Salmonella VNP20009 and hydroxychloroquine.
• To determine if liposomal hydroxychloroquine enhances Salmonella VNP20009 anti-tumor effects.
• To evaluate the combination's impact on tumor targeting, bacterial load, and cell death.

Main Methods:

• Combination therapy using Salmonella VNP20009 and liposomal hydroxychloroquine.
• In vitro studies assessing intracellular bacterial numbers, autophagic vacuoles, and cell death.
• In vivo studies using a murine melanoma model to evaluate tumor growth, targeting, and survival.

Main Results:

• The combination therapy resulted in significantly higher intracellular Salmonella VNP20009.
• Accumulated autophagic vacuoles and increased cell death were observed in vitro.
• Enhanced tumor targeting, slower tumor growth, and prolonged survival were noted in vivo compared to free hydroxychloroquine.

Conclusions:

• Combining tumor-targeting Salmonella VNP20009 with autophagy arrest via liposomal hydroxychloroquine shows promise.
• This strategy may overcome bacterial clearance mechanisms and enhance anti-cancer effects.
• The combination warrants further investigation for treating aggressive melanoma.